Human Genome Sciences News

The latest chapter in Human Genome Sciences' battle to fend off a hostile takeover bid by British pharma giant GlaxoSmithKline played out in a Rockville courtroom Thursday morning.

The British pharmaceutical giant is looking to replace the entire board of Human Genome Sciences , the biotechnology company it is trying to acquire for $2.59 billion, according to people with direct knowledge of the matter.

TWO of the most glamorous names in global finance are linking up, with the Rothschild banking dynasty agreeing to buy a stake in the Rockefeller group's wealth and asset management business to get a long-sought foothold in the United States.

Stocks dropped on Wednesday, as rising bond yields for Italy and Spain and the latest poll results in Greece worsened fears about a spiraling of the euro zone's debt crisis.

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

The board of Human Genome Sciences is being sued by a shareholder, and the court is being petitioned to stop the company from using its "poison pill" to prevent the $2.6 billion hostile takeover attempt by GlaxoSmithKline .

Asian shares edged higher but the euro eased on Tuesday, as a relief rally from last week's heavy selling proved short-lived, with a surge in Spanish borrowing costs adding to simmering worries about Europe's debt restructuring challenges.

Costco Wholesale Corporation : Baird raised its price target on Costco following Q3 results.

GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.

Green Dot was downgraded today by Morgan Stanley to equal weight from overweight with a price target of $25 due to competitive and regulatory pressures currently facing the company.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc.

Shares of Human Genome Sciences opened at 13.88 on Thursday. Human Genome Sciences has a one year low of $6.51 and a one year high of $30.00. The company's market cap is $2.763 billion.

GlaxoSmithKline Plc may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.

GlaxoSmithKline shares move lower Wednesday as the firm modifies the terms of its $2.6 billion tender offer for Human Genome , which require that its quarry redeem or invalidate its poison pill.

Just last month GlaxoSmithKline was in the news for a move to acquire Human Genome Sciences , its partner of up to twenty years for $2.6 billion.

Following GlaxoSmithKline's unsolicited $2.6-billion offer earlier this month for acquiring the biopharmaceutical company Human Genome Sciences , HGS announced late last week that its board of directors had unanimously determined that the offer of $13.00 per share undervalued HGS and issued a shareholder's rights plan advising stockholders to ... (more)

Diversified manufacturer Eaton Corp. is buying Irish electrical equipment supplier Cooper Industries PLC in a cash-and-stock deal valued at about $11.46 billion.

An interesting scenario is developing in the world of Sirius . For a while now, Liberty Media has been trying to gain control of Sirius XM.

Two items on Thursday from Human Genome Sciences , as it reports that adoption of a rights plan for short-term shareholders, which will have the term of one year.

Spanish stocks dropped sharply early Friday morning after ratings agency Moody's downgraded its credit score of 16 Spanish banks in the latest blow to the troubled financial sector.